2026-01-02 - Analysis Report
Okay, here's a comprehensive report analyzing Eli Lilly and Co (LLY) based on the provided data.

**1. Return Rate Comparison (LLY vs. VOO)**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company discovering, developing, manufacturing, and marketing pharmaceutical products.
*   **LLY Cumulative Return:** 281.99%
*   **VOO (S&P 500) Cumulative Return:** 91.40%
*   **Divergence:**
    *   Current: 176.9
    *   Relative Divergence: 83.1

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period for which the cumulative return was measured.  The current divergence of 176.9 indicates a substantial difference in returns. The relative divergence of 83.1 suggests the current divergence is high compared to its historical range of divergence with the S&P 500. This indicates a period of exceptional relative performance for LLY.

**Alpha, Beta Analysis:**

| Year      | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|-----------|-------|-------|-------|------|--------|
| 2016-2018 | 37.0% | 100.0% | 33.0% | 0.7  | 103.7  |
| 2017-2019 | 36.0% | 100.0% | 19.0% | 0.7  | 117.8  |
| 2018-2020 | 30.0% | 99.9% | 10.0% | 0.7  | 151.4  |
| 2019-2021 | 49.0% | 73.8%  | 5.0%  | 0.7  | 247.6  |
| 2020-2022 | 59.0% | 72.5%  | 60.0% | 0.7  | 328.0  |
| 2021-2023 | 116.0% | 41.7%  | 115.0% | 0.5  | 522.6  |
| 2022-2024 | 123.0% | 40.2%  | 104.0% | 0.6  | 692.1  |
| 2023-2025 | 183.0% | 50.2%  | 121.0% | 0.7  | 963.4  |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate demonstrates accelerating returns, especially in recent years (2021-2025).
*   **MDD:**  The Maximum Drawdown shows a decrease in risk over time.
*   **Alpha:**  Alpha consistently shows strong outperformance, implying that LLY's returns are not solely attributable to market movements.
*   **Beta:**  Beta remains relatively stable, fluctuating around 0.7, suggesting that LLY is less volatile than the market.
*   **Market Cap:** Market capitalization is steadily increasing, meaning growing investors' confidence.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 1074.68
*   **Previous Close:** 1079.75
*   **Change:** -0.47
*   **5-day SMA:** 1077.58
*   **20-day SMA:** 1044.57
*   **60-day SMA:** 964.42

**Analysis:** The current price is slightly below the previous close, indicating a marginal decrease. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This suggests a recent uptrend, although the slight dip from the previous close might warrant caution.

**3. RSI, PPO, MRI, and Expected Return Analysis**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 78.60
*   **PPO:** -0.14
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Relative Divergence Change:** 1.1 (+): 단기상승 (short-term rise)
*   **Expected Return:** 171.0%

**Analysis:**

*   **MRI:** The high MRI value suggests a favorable market environment for investment in LLY.
*   **RSI:** The RSI is above 70, indicating that LLY might be overbought. This could suggest a potential pullback in the near term.
*   **PPO:** The PPO value is slightly negative, which typically indicates bearish tendencies
*   **Hybrid Signal:** The signal suggests a strong buy recommendation.
*   **Recent Relative Divergence Change:** The recent increase in relative divergence confirms the recent outperformance of LLY.
*   **Expected Return:** A 171.0% expected return significantly exceeds the broader market, solidifying a bullish outlook.

**4. Recent News & Significant Events**

*   **Weight-loss pill pricing and insider filing:**  The news regarding weight-loss pill pricing indicates market focus on this area, crucial for LLY.
*   **Analyst consensus and price targets:** Generally positive sentiment from analysts is expected.
*   **Stock split candidate:** The suggestion of a stock split implies positive expectations of future growth.
*   **Stock Quote & Chart:** Most investors follow it to identify market situations.
*   **Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al:** Usually the shares have been sold due to the investors' strategy such as portfolio balancing
*   **Why Eli Lilly (LLY) Stock Is Trading Up Today:** Market participants are focusing on recent trading behavior

**Analysis:** The recent news portrays a mix of factors. The focus on weight-loss pill pricing is relevant to LLY's product pipeline.  The mention of a possible stock split indicates a bullish outlook. The trading up of LLY's stock indicates investors' confidence.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.70 (~Buy)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1093.22 / 1500.00 / 770.00

**Analysis:** Analysts generally have a "Buy" consensus on LLY with a considerable target price range.  The average target price is slightly above the current price, suggesting potential upside. However, it's crucial to consider the wide range between the high and low target prices, indicating a range of opinions on the stock's future.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.30 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

**Analysis:**

*   **Positive Trend:**  EPS and revenue have generally been increasing over the reported quarters, showing solid financial performance.
*   **Exceptional Growth in 2025:** The EPS for 2025-08-07 and 2025-10-30 is more than double compared to the one of 2024-10-30, indicating a rapid boost in performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30 | $17.60B    | 82.91%        |
| 2025-06-30 | $15.56B    | 84.27%        |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30 | $23.79B    | 23.46%    |
| 2025-06-30 | $18.27B    | 30.98%    |
| 2025-03-31 | $15.76B    | 17.50%    |
| 2024-12-31 | $14.19B    | 31.07%    |
| 2024-09-30 | $14.24B    | 6.81%     |

**Analysis:**

*   **Revenue Growth:** Revenue has consistently increased over the reported periods.
*   **High Profit Margin:** Consistently high profit margins suggest efficient operations.
*   **Growing Equity:** Equity has steadily increased, indicating the company is building value.
*   **Strong ROE:** The ROE has fluctuated, but is generally strong, implying effective use of shareholder equity to generate profits.

**7. Comprehensive Analysis (Summary)**

Eli Lilly and Co. (LLY) is exhibiting a strong performance and is well-positioned for future growth, based on the available data. Here's a summary of key findings:

*   **Outperformance:** LLY has significantly outperformed the S&P 500.
*   **Strong Financials:** Revenue, EPS, and profit margins demonstrate strong performance.
*   **Bullish Outlook:** Analyst consensus, MRI, and expected return metrics suggest a favorable investment environment.
*   **Potential Overbought Condition:** The RSI indicates that LLY is overbought, which might lead to a short-term pullback.
*   **Growth Catalysts:** Positive coverage indicates continuous growth.

**In Conclusion:** While the stock seems somewhat overbought in the short term, the overall outlook for LLY appears positive, supported by strong financials, growth catalysts, and analyst sentiment. However, carefully consider the risk related to the negative PPO index and short-term drop.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.